Patents by Inventor James Lorens

James Lorens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7566546
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Sacha J. Holland, Weiduan Xu
  • Patent number: 7532922
    Abstract: A system and method for translating a patient table is described. The described patient table includes a linearly translatable portion, a drive screw assembly, a power transmission assembly, and a drive train. The translatable portion is configured to be positioned in a plurality of selectable positions between a fully inserted position and a fully extracted position. The drive screw assembly includes a drive nut and a screw member. The drive nut is fixedly coupled to the translatable portion of the patient table and threadily engaged to the screw member. The screw member is drivingly coupled to the power transmission assembly. The drive train is configured to drive the translatable portion of the patient table at a predetermined insertion force in the insertion direction, and a predetermined extraction force in the extraction direction. The predetermined extraction force is greater than the predetermined insertion force.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: May 12, 2009
    Assignee: General Electric Company
    Inventors: Chad Allan Smith, Kyle Marcus Johnson, Timothy Matthew Behlmer, James Loren Dodge
  • Patent number: 7527936
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: May 5, 2009
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Weiduan Xu, Sacha J. Holland, James Lorens
  • Publication number: 20070172818
    Abstract: The invention relates to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.
    Type: Application
    Filed: December 7, 2006
    Publication date: July 26, 2007
    Inventors: Joseph Fisher, James Lorens, Donald Payan, Alexander Rossi
  • Publication number: 20070166769
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Application
    Filed: March 7, 2007
    Publication date: July 19, 2007
    Inventors: James Lorens, Jakob Bogenberger
  • Publication number: 20070105140
    Abstract: The present invention relates to methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.
    Type: Application
    Filed: October 4, 2006
    Publication date: May 10, 2007
    Inventors: James Lorens, Todd Kinsella, Todd Pray, Mark Bennett
  • Patent number: 7205130
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Jakob M. Bogenberger
  • Publication number: 20060264392
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic adds, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: September 2, 2003
    Publication date: November 23, 2006
    Inventors: James Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
  • Publication number: 20060147978
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Application
    Filed: February 24, 2006
    Publication date: July 6, 2006
    Inventors: James Lorens, Todd Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Liao, Denise Pearsall, Annabelle Friera, Peter Chu
  • Patent number: 7056687
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: June 6, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Freiro, Peter Chu
  • Publication number: 20050260626
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Application
    Filed: February 28, 2005
    Publication date: November 24, 2005
    Inventors: James Lorens, Todd Pray, Todd Kinsella, Mark Bennett
  • Publication number: 20050250163
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 10, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Sacha Holland, Weiduan Xu
  • Publication number: 20050208472
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: January 13, 2005
    Publication date: September 22, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Weiduan Xu, Sacha Holland, James Lorens
  • Publication number: 20050118604
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: October 29, 2003
    Publication date: June 2, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Robert Atchison, Annabelle Friera, Sacha Holland
  • Patent number: 6897031
    Abstract: Described is a method for screening for alterations in exocytosis of a population of cells. The cells are sorted by a FACS machine by assaying for alterations in at least three of the properties selected from the group consisting of light scattering, fluorescent dye uptake, fluorescent dye release, annexin granule binding, surface granule enzyme activity, and the quantity of granule specific proteins. Methods for screening for bioactive agents capable of modulating exocytosis in a cell are also described. The methods provide for reduced background and increased specificity without increasing the time or steps involved in assaying for exocytosis.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: May 24, 2005
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Joseph Fisher, James Lorens, Donald Payan, Alexander Rossi
  • Publication number: 20040005593
    Abstract: The present invention relates to methods of screening for target polypeptides that bind to RNA, using affinity purification methods, and the use of such target polypeptide for drug discovery and in methods of treating and preventing disease.
    Type: Application
    Filed: March 6, 2003
    Publication date: January 8, 2004
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: James Lorens
  • Publication number: 20030211535
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Application
    Filed: May 8, 2002
    Publication date: November 13, 2003
    Inventors: James Lorens, Jakob M. Bogenberger
  • Patent number: 6645766
    Abstract: The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5′ and 3′ ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: November 11, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Pei Wen Yu, James Lorens
  • Patent number: 6623980
    Abstract: The present invention is directed to novel exocytotic polypeptides, such as Exo1 and Exo2 polypeptides and related molecules, which have an inhibitory effect on exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which mediate exocytotic polypeptide bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: September 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Joseph Fisher, James Lorens, David Anderson, Ying Luo, Chao Bai (Betty) Huang, Mary Shen
  • Publication number: 20030022196
    Abstract: The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.
    Type: Application
    Filed: March 8, 2002
    Publication date: January 30, 2003
    Inventors: James Lorens, Todd M. Kinsella, Esteban Masuda, Yasumichi Hitoshi, X. Charlene Liao, Denise Pearsall, Annabelle Friera, Peter Chu